Related Experiment Video

Updated: Aug 7, 2026

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Devansu Tewari1, Bahman Saffari, Carol Cowan

  • 1Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.

Gynecologic Oncology
|June 27, 2006
PubMed
Abstract

Insights

Trabectedin shows promise for treating uterine leiomyosarcoma, a rare cancer with a poor prognosis. This study details a patient who achieved a durable response to trabectedin (ET-743) after other treatments failed.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Uterine leiomyosarcomas have a poor prognosis, necessitating novel therapeutic strategies.
  • Effective treatment options for advanced, recurrent, and refractory uterine leiomyosarcomas are limited.

Observation:

  • A single patient with advanced, recurrent, and refractory uterine leiomyosarcoma was treated with trabectedin (ET-743).
  • The treatment involved intravenous administration of trabectedin at 1.2 mg/m2 over 24 hours every 3 weeks.

Findings:

  • The patient exhibited a durable objective response to trabectedin lasting at least 8 months.
  • Trabectedin demonstrated significant activity in this refractory uterine leiomyosarcoma case, even after failure of four prior regimens.

Implications:

  • Trabectedin (ET-743) presents a potential therapeutic option for uterine leiomyosarcoma.
  • Further clinical investigation of trabectedin for uterine leiomyosarcoma is warranted to confirm its efficacy and safety.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...